Orchid Pharma antibiotic product for treating UTI coming to India: MD

Company says it's returning to profit after takeover by Dhanuka Laboratories under insolvency resolution

Orchid Pharma, which was taken over by Dhanuka Laboratories under insolvency resolution in March 2020, is making a turn-around in revenue and profit as it commercialises a molecule developed in-house, said its senior executive.

Manish Dhanuka, managing director of Chennai-based Orchid Pharma, told Business Standard the new chemical entity (NCE) is known as Enmetazobactam. The molecule is a BLI (Beta-lactamase Inhibitor) used in combination with beta-lactam antibiotic cefepime.

“The drug product which has completed global clinical trials is a combination of Enmetazobactam with Cefepime. This is an injectable product, which is highly effective in treating complicated Urinary Tract Infections (cUTI),” Dhanuka